With co­va­lent meds abuzz, RA Cap­i­tal and No­var­tis lead $56M seed round for new start­up

See­ing the suc­cess­es of oth­er co­va­lent med­i­cines com­pa­nies, a group of blue-chip in­vestors is lin­ing up to take the next shot on goal.

RA Cap­i­tal, typ­i­cal­ly known for its late-stage and crossover in­vest­ments, is get­ting in on the ground floor at Hyku Bio­sciences, a new biotech that emerged from stealth Tues­day morn­ing. RA and its in­cu­ba­tor, RAVen, led a $56 mil­lion seed round for Hyku along­side Droia Ven­tures and No­var­tis Ven­ture Fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.